Randomized, double-blind, placebo-controlled study on effects of raloxifene and hormone replacement therapy on plasma NO concentrations, endothelin-1 levels, and endothelium-dependent vasodilation in postmenopausal women

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 21, Issue 9, 2001, Pages 1512-1519

  Saitta, Antonino ^a   Altavilla, Domenica ^b   Cucinotta, Domenico ^a   Morabito, Nunziata ^a   Frisina, Nicola ^a   Corrado, Francesco ^a   D'Anna, Rosario ^a   Lasco, Antonino ^a   Squadrito, Giovanni ^a   Gaudio, Agostino ^a   Cancellieri, Francesco ^a   Arcoraci, Vincenzo ^b   Squadrito, Francesco ^a,b  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

Author keywords

Endothelin 1; Endothelium; Hormone replacement therapy; Nitric oxide; Raloxifene

Indexed keywords

ENDOTHELIN 1; ESTRADIOL PLUS NORETHISTERONE ACETATE; ESTROGEN; ESTROGEN RECEPTOR; NITRIC OXIDE; PLACEBO; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ADULT; ARTICLE; ATHEROSCLEROSIS; BRACHIAL ARTERY; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; ENDOTHELIUM CELL; FEMALE; FLOW KINETICS; HORMONE RECEPTOR INTERACTION; HORMONE SUBSTITUTION; HUMAN; HUMAN EXPERIMENT; MORBIDITY; MORTALITY; NORMAL HUMAN; OXIDATIVE STRESS; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; VASCULAR ENDOTHELIUM; VASODILATATION;

EID: 0035572888     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/hq0901.095565     Document Type: Article

References (61)

1. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease
2. Estrogen and coronary heart disease in women
3. Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidence
4. Postmenopausal estrogen therapy and cardiovascular disease: Ten-year follow-up from the nurses' health study
5. Hormonal treatment of postmenopausal women
6. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women
7. The vascular protective effects of estrogens
8. Ethinyl estradiol acutely attenuates abnormal coronary vasomotor responses to acetylcholine in postmenopausal women
9. Effects of physiological levels of estrogen on coronary vasomotor function in postmenopausal women
10. Effect of conjugated estrogen on peripheral flow mediated vasodilation in postmenopausal women
11. Estrogen improves endothelial-dependent flow-mediated vasodilation in postmenopausal women
12. Estrogen modulates responses of atherosclerotic coronary arteries
13. Effects of hormone replacement therapy on reactivity of atherosclerotic coronary arteries in cynomolgus monkeys
14. Regulatory functions of the vascular endothelium
15. Endothelial dysfunction in coronary heart disease
16. Endothelial dysfunction: Does it matter? Is it reversible?
17. Cholesterol reduction in cardiovascular disease: Clinical benefits and possible mechanisms
18. Chronic inhibition of nitric oxide production accelerates neointima formation and impairs endothelial function in hypercholesterolemic rabbits
19. Long term oral administration of L-arginine reduces intimal thickening and enhances neoendothelium-dependent acetylcholine-induced relaxation after arterial injury
20. Circulating nitric oxide (nitrite/nitrate) levels in postmenopausal women substituted with 17β-estradiol and norethisterone acetate: A two-year follow-up study
21. Postmenopausal hormonal replacement decreases plasma levels of endothelin-1
22. Acute vascular effects of estrogen in postmenopausal women
23. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
24. Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer
25. Combined hormone replacement therapy does not protect women against the age-related decline in endothelium-dependent vasomotor function
26. The use of estrogen and progestins and the risk of breast cancer in postmenopausal women
27. Estrogen promotes angiogenic activity in human umbilical vein endothelial cells in vitro and in a murine model
28. Paradoxical influence of estrogenic hormones on platelet endothelial cells interactions
29. Effect of 17-β estradiol on inhibition of platelet aggregation in vitro is mediated by an increase in NO synthesis
30. Effects of hormone replacement therapy on fibrinolysis in postmenopausal women
31. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women: A randomized controlled trial
32. Raloxifene is a tissue-selective agonist/antagonist that functions through the estrogen receptor
33. Raloxifene (LY 139481 HCl) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats
34. Advantages of raloxifene over alendornate or estrogen on non-reproductive tissues in the long-term dosing of ovariectomized rats
35. Raloxifene preserves bone strength and bone mass in ovariectomized rats
36. A controlled trial of raloxifene (LY 158481) HCl: Impact on bone turnover and serum lipid profile in healthy postmenopausal women
37. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women
38. Raloxifene inhibits aortic accumulation of cholesterol in ovariectomized cholesterol-fed rabbits
39. Lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys
40. Raloxifene acutely relaxes rabbit coronary arteries in vitro by an estrogen receptor-dependent and nitric oxide-dependent mechanism
41. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women
42. Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women: A 2-year, placebo-controlled study
43. Raloxifene lowers serum lipoprotein(A) in healthy postmenopausal women: A randomized, double-blind, placebo-controlled comparison with conjugated equine estrogens
44. Randomized, double-blind, placebo-controlled study of the effects of raloxifene and conjugated equine estrogen on plasma homocysteine levels in healthy postmenopausal women
45. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: A randomized, controlled trial
46. Endothelial dysfunction in atherosclerosis
47. Endothelin in coronary endothelial dysfunction and early atherosclerosis in humans
48. Vasodilator-derived nitric oxide inhibits fetal calf serum and angiotensin-II-induced growth of renal arteriolar smooth muscle cells
49. Nitric oxide and its role in the cardiovascular system
50. The role of endothelin in coronary atherosclerosis
51. Release of endothelin from the porcine aorta: Inhibition by endothelium-derived nitric oxide
52. The effect of estrogen replacement therapy on plasma nitric oxide and endothelin-1 levels in postmenopausal women
53. The long-term effects of oral and transdermal postmenopausal hormone replacement therapy on nitric oxide, endothelin-1, prostacyclin, and thromboxane
54. Effects of estrogen replacement therapy on plasma levels of nitric oxide in postmenopausal women
55. Raloxifene acutely stimulates nitric oxide release from human endothelial cells via an activation of endothelial nitric oxide synthase
56. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women
57. Efficacy of Levormeloxifene in the prevention of postmenopausal bone loss and on lipid profile compared to low dose hormone replacement therapy
58. Effect of oral postmenopausal hormone replacement on progression of atherosclerosis: A randomized, controlled trial
59. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction
60. Endothelial dysfunction in arterial hypertension
61. Early endothelial dysfunction predicts the development of transplant coronary artery disease at 1 year post-transplant